Arbutus Biopharma Corporation
ABUS
$3.29
-$0.05-1.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -69.92M | -76.70M | -77.09M | -74.39M | -72.85M |
| Total Depreciation and Amortization | 1.38M | 1.41M | 1.44M | 1.43M | 1.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.52M | 4.58M | 4.77M | 3.79M | 3.74M |
| Change in Net Operating Assets | -2.83M | -1.11M | -2.00M | -8.76M | -18.23M |
| Cash from Operations | -64.85M | -71.83M | -72.88M | -77.93M | -85.94M |
| Capital Expenditure | -182.00K | -96.00K | -128.00K | -986.00K | -1.01M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 20.00K | 20.00K | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.13M | 31.86M | 54.29M | 46.76M | 51.76M |
| Cash from Investing | 22.95M | 31.76M | 54.18M | 45.79M | 50.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 52.00M | 54.38M | 54.29M | 34.66M | 30.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 52.00M | 54.38M | 54.29M | 34.66M | 30.65M |
| Foreign Exchange rate Adjustments | -49.00K | -2.00K | 1.00K | 8.00K | 25.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.05M | 14.32M | 35.59M | 2.53M | -4.49M |